Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient

Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient

Abstract Background The compound letermovir (LMV) has recently been approved for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV seropositive recipients of an allogeneic hematopoietic stem cell transplant. LMV inhibits CMV replication by binding to the viral terminase com...

Description complète

Détails bibliographiques
Auteurs principaux: Susanne Jung, Manuela Michel, Thomas Stamminger, Detlef Michel
Format: Article
Langue:English
Publié: BMC 2019-05-01
Collection:BMC Infectious Diseases
Sujets:
Antiviral resistance
Cytomegalovirus
Letermovir
Genotyping
Allogenic hematopoietic-cell transplantation
Acute myeloid leukemia
Accès en ligne:http://link.springer.com/article/10.1186/s12879-019-4016-1

Internet

http://link.springer.com/article/10.1186/s12879-019-4016-1

Documents similaires